{"id":388156,"date":"2020-11-24T16:44:02","date_gmt":"2020-11-24T21:44:02","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=388156"},"modified":"2020-11-24T16:44:02","modified_gmt":"2020-11-24T21:44:02","slug":"aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/","title":{"rendered":"Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">AUSTIN, Texas<\/span>, <span class=\"xn-chron\">Nov. 24, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced updated timing for its Fireside Chat presentation at an upcoming investor conference hosted by Evercore. <\/p>\n<p>\n        <b>Updated Conference Details<\/b>\n      <\/p>\n<p>Conference Name: Evercore ISI 3rd\u00a0Annual HealthCONx Conference<br \/>Conference Date:\u00a0December 1-3, 2020<br \/>Fireside Chat Date\/Time: <span class=\"xn-chron\">December 1, 2020<\/span> at <span class=\"xn-chron\">8:00 a.m. EST<\/span><br \/>Presenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea&#8217;s president and chief executive officer<\/p>\n<p>To access the live and archived webcast, visit the <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2992838-1&amp;h=2236622134&amp;u=http%3A%2F%2Fir.aegleabio.com%2Fevents-and-presentations%2Fupcoming-events&amp;a=Presentations+%26+Events\" rel=\"nofollow noopener noreferrer\">Presentations &amp; Events<\/a> section of the Company&#8217;s website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. An archived version of the webcasts will also be available through the Company&#8217;s website for a limited time following the conference.<\/p>\n<p>\n        <b>About Aeglea BioTherapeutics<\/b>\n      <\/p>\n<p>Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea&#8217;s lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. The Company initiated a Phase 1\/2 clinical trial of ACN00177 for the treatment of Homocystinuria in the second quarter of 2020. Aeglea has an active discovery platform, with the most advanced program for Cystinuria. For more information, please visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2992838-1&amp;h=485138959&amp;u=http%3A%2F%2Faegleabio.com%2F&amp;a=http%3A%2F%2Faegleabio.com\" rel=\"nofollow noopener noreferrer\">http:\/\/aegleabio.com<\/a>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder6258\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg\" title=\"(PRNewsfoto\/Aeglea BioTherapeutics, Inc.)\" alt=\"(PRNewsfoto\/Aeglea BioTherapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DA03161&amp;sd=2020-11-24\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference-301180126.html\">http:\/\/www.prnewswire.com\/news-releases\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference-301180126.html<\/a><\/p>\n<p>SOURCE  Aeglea BioTherapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DA03161&amp;Transmission_Id=202011241640PR_NEWS_USPR_____DA03161&amp;DateId=20201124\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire AUSTIN, Texas, Nov. 24, 2020 \/PRNewswire\/ &#8212;\u00a0Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced updated timing for its Fireside Chat presentation at an upcoming investor conference hosted by Evercore. Updated Conference Details Conference Name: Evercore ISI 3rd\u00a0Annual HealthCONx ConferenceConference Date:\u00a0December 1-3, 2020Fireside Chat Date\/Time: December 1, 2020 at 8:00 a.m. ESTPresenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea&#8217;s president and chief executive officer To access the live and archived webcast, visit the Presentations &amp; Events section of the Company&#8217;s website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-388156","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire AUSTIN, Texas, Nov. 24, 2020 \/PRNewswire\/ &#8212;\u00a0Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced updated timing for its Fireside Chat presentation at an upcoming investor conference hosted by Evercore. Updated Conference Details Conference Name: Evercore ISI 3rd\u00a0Annual HealthCONx ConferenceConference Date:\u00a0December 1-3, 2020Fireside Chat Date\/Time: December 1, 2020 at 8:00 a.m. ESTPresenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea&#8217;s president and chief executive officer To access the live and archived webcast, visit the Presentations &amp; Events section of the Company&#8217;s website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that &hellip; Continue reading &quot;Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T21:44:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference\",\"datePublished\":\"2020-11-24T21:44:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\\\/\"},\"wordCount\":271,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1319229\\\/Aeglea_BioTherapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\\\/\",\"name\":\"Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1319229\\\/Aeglea_BioTherapeutics_Logo.jpg\",\"datePublished\":\"2020-11-24T21:44:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1319229\\\/Aeglea_BioTherapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1319229\\\/Aeglea_BioTherapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference - Market Newsdesk","og_description":"PR Newswire AUSTIN, Texas, Nov. 24, 2020 \/PRNewswire\/ &#8212;\u00a0Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced updated timing for its Fireside Chat presentation at an upcoming investor conference hosted by Evercore. Updated Conference Details Conference Name: Evercore ISI 3rd\u00a0Annual HealthCONx ConferenceConference Date:\u00a0December 1-3, 2020Fireside Chat Date\/Time: December 1, 2020 at 8:00 a.m. ESTPresenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea&#8217;s president and chief executive officer To access the live and archived webcast, visit the Presentations &amp; Events section of the Company&#8217;s website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that &hellip; Continue reading \"Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-24T21:44:02+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference","datePublished":"2020-11-24T21:44:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/"},"wordCount":271,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/","name":"Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg","datePublished":"2020-11-24T21:44:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=388156"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388156\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=388156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=388156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=388156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}